“In essence, big pharma often uses a "crawl, walk, run"...

“In essence, big pharma often uses a "crawl, walk, run" approach, starting with a focused indication to de-risk development and then expanding to larger, more competitive markets as the drug proves its value”
“it's common for large pharmaceutical companies (big pharma) to initially target specific, often smaller, cancer indications (like rare cancers or specific subtypes) as they become successful with a drug. This approach allows them to build a foundation of evidence for the drug's efficacy and safety in a more manageable setting, before expanding to broader, more competitive indications”